Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.
Carol MilliganNazem AtassiSuma BabuRichard J BarohnJames B CaressMerit E CudkowiczArmineuza EvoraGregory A HawkinsMarlena Wosiski-KuhnEric A MacklinJeremy M ShefnerZachary SimmonsRobert P BowserShafeeq S LadhaPublished in: Muscle & nerve (2021)
Tocilizumab treatment was safe and well tolerated. PBMC gene expression profile was inadequate as a predictive or pharmacodynamic biomarker. Treatment reduced CRP levels in plasma and CSF, with CSF effects potentially dependent on IL-6R Asp358 Ala genotype. IL-6 trans-signaling may mediate a distinct central nervous system response in individuals inheriting the IL-6R C allele. These results warrant further study in ALS patients where IL-6R genotype and CRP levels may be useful enrichment biomarkers.
Keyphrases
- end stage renal disease
- cerebrospinal fluid
- newly diagnosed
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- juvenile idiopathic arthritis
- patient reported outcomes
- genome wide
- copy number
- rheumatoid arthritis patients
- replacement therapy
- dna methylation
- smoking cessation